Description: Krystal Biotech, Inc. gene therapy company. The Company is engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. The Company has developed a Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases. The Company’s products include KB103 and KB104.The Compnay's KB103 is in preclinical development to treat dystrophic epidermolysis bullosa, or DEB, a rare and severe genetic disease. The Compnay's KB104 is to treat Netherton Syndrome, a severe form of ichthyosis, which is a family of genetic skin disorders associated with thickened scaly skin and characterized by chronic skin inflammation, itchiness, dehydration and stunted growth.
Home Page: www.krystalbio.com
KRYS Technical Analysis
2100 Wharton Street
Pittsburgh,
PA
15203
United States
Phone:
412 586 5830
Officers
| Name | Title |
|---|---|
| Mr. Krish S. Krishnan M.B.A., M.S. | Founder, Chairman, Pres & CEO |
| Ms. Suma M. Krishnan | Founder, COO, Pres of R&D and Director |
| Ms. Kathryn A. Romano | Exec. VP & Chief Accounting Officer |
| Dr. Andreas C. Orth | Exec. VP & Chief Commercial Officer |
| Ms. Gloria Lin | Accounting Mang. |
| Mr. Ram Kamineni | Sr. VP of CMC & Technical Operations |
| Ms. Meg Dodge | VP of Investor Relations & Corp. Communications |
| Mr. David Glynn | Gen. Counsel, Commercial & Compliance |
| Mr. John Karakkal | VP of North American Sales & Marketing |
| Ms. Katherine Tuminello | HR & Office Mang. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.3819 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2017-09-20 |
| Fiscal Year End: | December |
| Full Time Employees: | 119 |